Insomnia, the struggle to fall asleep or stay asleep, disrupts millions of lives worldwide. Lemborexant, a new class of medication known as dual orexin receptor antagonists (DORAs), has emerged as a promising treatment option. However, for this promise to be fully realized, pharmaceutical companies must address critical formulation considerations surrounding the Lemborexant Active...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian